Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies

Biological Psychiatry

Volumn 64, Issue 10, 2008, Pages 850-855

  Parnetti, Lucilla ^a   Tiraboschi, Pietro ^c,d   Lanari, Alessia ^a   Peducci, Maria ^a,b   Padiglioni, Chiara ^a,b   D'Amore, Cataldo ^a,b   Pierguidi, Laura ^a,b   Tambasco, Nicola ^a   Rossi, Aroldo ^a   Calabresi, Paolo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d Ospedale Briolini   (Italy)

Author keywords

CSF biomarkers; dementia; dementia with Lewy bodies; Parkinson's disease; Parkinson's disease with dementia; parkinsonisms

Indexed keywords

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DEMENTIA; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 47049100511     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.02.016     Document Type: Article

References (45)

1. Cummings J.L. Intellectual impairment in Parkinson's disease: Clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 51 (1988) 244-249
2. Aarsland D., Perry R., Brown A., Larsen J.P., and Ballard C. Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. Ann Neurol 58 (2005) 773-776
3. Merdes A.R., Hansen L.A., Jeste D.V., Galasko D., Hofstetter C.R., Ho G.J., et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60 (2003) 1586-1590
4. Aarsland D., Ballard C.G., and Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?. J Geriatr Psychiatry Neurol 17 (2004) 137-145
5. Guo L., Itaya M., Takanashi M., Mizuno Y., and Mori H. Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat Disord 11 (2005) 305-309
6. Tsuboi Y., and Dickson D.W. Dementia with Lewy bodies and Parkinson's disease with dementia: Are they different?. Parkinsonism Relat Disord 11 (2005) S47-S51
7. Braak H., Rub U., Jansen Steur E.N., Del Tredici K., and de Vos R.A. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64 (2005) 1404-1410
8. Duyckaerts C., Gaspar P., Costa C., Bonnet A.M., and Hauw J.J. Dementia in Parkinson's disease. Morphometric data. Adv Neurol 60 (1993) 447-455
9. Mori H. Pathological substrate of dementia in Parkinson's disease-its relation to DLB and DLBD. Parkinsonism Relat Disord 11 (2005) S41-S45
10. Apaydin H., Ahlskog J.E., Parisi J.E., Boeve B.F., and Dickson D.W. Parkinson disease neuropathology: Later-developing dementia and loss of the levodopa response. Arch Neurol 59 (2002) 102-112
11. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54 (2000) 1916-1921
12. Mattila P.M., Rinne J.O., Helenius H., Dickson D.W., and Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 100 (2000) 285-290
13. Levy G. Dementia in Parkinson's disease challenges the "gold standard.". Ann Neurol 58 (2005) 663-665
14. Giasson B.I., Forman M.S., Higuchi M., Golbe L.I., Graves C.L., Kotzbauer P.T., et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300 (2003) 636-640
15. Galpern W.R., and Lang A.E. Interface between tauopathies and synucleinopathies: A tale of two proteins. Ann Neurol 59 (2006) 449-458
16. Strozyk D., Blennow K., White L.R., and Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 (2003) 652-656
17. Hampel H., Mitchell A., Blennow K., Frank R.A., Brettschneider S., Weller L., and Moller H.J. Core biological marker candidates of Alzheimer's disease-perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 111 (2004) 247-272
18. Augustinack J.C., Schneider A., Mandelkow E.M., and Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103 (2002) 26-35
19. Blennow K., and Hampel H. Cerebrospinal fluid markers for incipient Alzheimer's disease. Lancet Neurol 2 (2003) 605-613
20. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5 (2006) 228-234
21. Parnetti L., Lanari A., Silvestrelli G., Saggese E., and Reboldi P. Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers. Mech Ageing Dev 127 (2006) 129-132
22. Vanderstichele H., De Vreese K., Blennoe K., Andreasen N., Sindic C., and Ivanoiu A. Analytical performance and clinical utility of INNOTEST PHOSPHO-TAU (181P) for discrimation between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 44 (2006) 1472-1480
23. Gomez-Tortosa E., Gonzalo I., Fanjul S., Sainz M.J., Cantarero S., Cemillan C., et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 60 (2003) 1218-1222
24. Kanemaru K., Kameda N., and Yamanouchi H. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology 54 (2000) 1875-1876
25. Mollenhauer B., Cepek L., Bibl M., Wiltfang J., Schulz-Schaeffer W.J., Ciesielczyk B., et al. Tau protein, Aβ42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19 (2005) 164-170
26. Bibl M., Mollenhauer B., Esselmann H., Lewczuk P., Trenkwalder C., Brechlin P., et al. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J Neural Transm 113 (2006) 1771-1778
27. Mollenhauer B., Trenkwalder C., von Ahsen N., Bibl M., Steinacker P., Brechlin P., et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 22 (2006) 200-208
28. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
29. Brazzelli M., Capitani E., Della Sala S., Spinnler H., and Zuffi M. A neuropsychological instrument adding to the description of patients with suspected cortical dementia: The Milan overall dementia assessment. J Neurol Neurosurg Psychiatry 57 (1994) 1510-1517
30. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., and Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
31. Walker M.P., Ayre G.A., Cummings J.L., Wesnes K., McKeith I.G., O'Brien J.T., and Ballard C.G. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology 54 (2000) 1616-1625
32. Gelb D.J., Oliver E., and Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 56 (1999) 33-39
33. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
34. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
35. Ballard C., Ziabreva I., Perry R., Larsen J.P., O'Brien J., McKeith I., et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67 (2006) 1931-1934
36. Lippa C.F., Duda J.E., Grossman M., Hurtig H.I., Aarsland D., Boeve B.F., et al. DLB and PDD boundary issues. Diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68 (2007) 812-819
37. Jellinger K.A. Pathological substrate of dementia in Parkinson's disease-its relation to DLB and DLBD. Parkinsonism Relat Disord 12 (2006) 119-120
38. Harding A.J., and Halliday G.M. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 102 (2001) 355-363
39. Mastaglia F.L., Johnsen R.D., Byrnes M.L., and Kakulas B.A. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Mov Disord 18 (2003) 81-86
40. Hansen L.A. The Lewy body variant of Alzheimer disease. J Neural Transm Suppl 51 (1997) 83-93
41. Jellinger K.A., Seppi K., Wenning G.K., and Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109 (2002) 329-339
42. Tschampa H.J., Schulz-Schaeffer W., Wiltfang J., Poser S., Otto M., Neumann M., and Kretzschmar H.A. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 56 (2001) 576
43. Wenning G.K., and Jellinger K.A. The role of alpha-synuclein and tau in neurodegenerative movement disorders. Curr Opin Neurol 18 (2005) 357-362
44. Mollenhauer B., Bibl M., Wiltfang J., Steinacker P., Ciesielczyk B., Neubert K., et al. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 44 (2005) 192-195
45. Tiraboschi P., Hansen L.A., Thal L.J., and Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62 (2004) 1984-1989